MEDAG

Summary

MEDAG (mesenteric estrogen dependent adipogenesis, HGNC:25926) is a protein-coding gene on chromosome 13q12.3, encoding Mesenteric estrogen-dependent adipogenesis protein (Q5VYS4). Involved in processes that promote adipocyte differentiation, lipid accumulation, and glucose uptake in mature adipocytes.

Predicted to be involved in positive regulation of fat cell differentiation. Located in cytoplasm.

Source: NCBI Gene 84935 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 59 total
• MANE Select transcript: NM_032849

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25926
Approved symbol	MEDAG
Name	mesenteric estrogen dependent adipogenesis
Location	13q12.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ14834, AWMS3, MEDA-4
Ensembl gene	ENSG00000102802
Ensembl biotype	protein_coding
Entrez	84935

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000380482, ENST00000428944, ENST00000904728, ENST00000968515

RefSeq mRNA: 1 — MANE Select: NM_032849 NM_032849

CCDS: CCDS9338

Canonical transcript exons

ENST00000380482 — 5 exons

Exon	Start	End
ENSE00000679979	30921561	30921846
ENSE00000679985	30921014	30921126
ENSE00001005822	30917403	30917512
ENSE00001485140	30924311	30925572
ENSE00001485154	30906271	30906793

Expression profiles

Bgee: expression breadth ubiquitous, 205 present calls, max score 98.37.

FANTOM5 (CAGE): breadth broad, TPM avg 21.7234 / max 594.5062, expressed in 691 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
134641	21.3736	687
134642	0.3498	162

Top tissues by expression

240 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	98.37	gold quality
synovial joint	UBERON:0002217	97.68	gold quality
descending thoracic aorta	UBERON:0002345	97.43	gold quality
vena cava	UBERON:0004087	97.42	gold quality
thoracic aorta	UBERON:0001515	97.27	gold quality
ascending aorta	UBERON:0001496	97.26	gold quality
pericardium	UBERON:0002407	97.23	gold quality
omental fat pad	UBERON:0010414	96.81	gold quality
peritoneum	UBERON:0002358	96.80	gold quality
layer of synovial tissue	UBERON:0007616	96.79	gold quality
decidua	UBERON:0002450	96.67	gold quality
adipose tissue of abdominal region	UBERON:0007808	96.39	gold quality
germinal epithelium of ovary	UBERON:0001304	95.99	gold quality
aorta	UBERON:0000947	95.98	gold quality
tendon	UBERON:0000043	95.41	gold quality
tendon of biceps brachii	UBERON:0008188	95.34	gold quality
tibial artery	UBERON:0007610	95.09	gold quality
popliteal artery	UBERON:0002250	95.08	gold quality
cardiac muscle of right atrium	UBERON:0003379	94.86	silver quality
cartilage tissue	UBERON:0002418	94.84	gold quality
mucosa of stomach	UBERON:0001199	94.66	gold quality
subcutaneous adipose tissue	UBERON:0002190	94.55	gold quality
parietal pleura	UBERON:0002400	94.54	gold quality
left uterine tube	UBERON:0001303	93.85	gold quality
saphenous vein	UBERON:0007318	93.37	gold quality
left coronary artery	UBERON:0001626	93.32	gold quality
coronary artery	UBERON:0001621	93.31	gold quality
right coronary artery	UBERON:0001625	92.97	gold quality
adipose tissue	UBERON:0001013	92.94	gold quality
cauda epididymis	UBERON:0004360	91.59	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-MTAB-8142	yes	1292.94
E-HCAD-15	yes	979.09
E-CURD-126	yes	755.21
E-GEOD-130148	yes	4.06
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

54 targeting MEDAG, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-4639-5P	99.81	67.37	1028
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-199A-3P	99.75	70.48	929
HSA-MIR-199B-3P	99.75	70.48	929
HSA-MIR-3129-5P	99.75	70.46	914
HSA-MIR-4255	99.72	67.70	1541
HSA-MIR-5700	99.64	69.88	2280
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-7150	99.62	66.80	1322
HSA-MIR-6073	99.60	70.36	793
HSA-MIR-888-3P	99.53	69.77	1057
HSA-MIR-12117	99.50	67.57	868
HSA-MIR-143-3P	99.49	69.05	1457
HSA-MIR-4770	99.49	69.09	1451
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-657	99.48	66.02	848
HSA-MIR-12131	99.48	68.72	1673
HSA-MIR-122B-5P	99.46	70.81	1457
HSA-MIR-4251	99.40	69.19	3363

Literature-anchored findings (GeneRIF, showing 3)

• study identifies Meda-4 as a novel adipogenic gene, capable of promoting differentiation of preadipocytes into adipocytes, increasing lipid content and glucose uptake in adipocytes; it might play an important role in adipose tissue expansion in normal and aberrant hormonal conditions and pathophysiological states (PMID:22510272)
• MEDAG expression is significantly upregulated in human masticatory mucosa during wound healing (PMID:28005267)
• Identification of MEDAG as a Hub Candidate Gene in the Onset and Progression of Type 2 Diabetes Mellitus by Comprehensive Bioinformatics Analysis. (PMID:33728329)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Medag	ENSMUSG00000029659
rattus_norvegicus	Medag	ENSRNOG00000000906

Protein

Protein identifiers

Mesenteric estrogen-dependent adipogenesis protein — Q5VYS4 (reviewed: Q5VYS4)

Alternative names: Activated in W/Wv mouse stomach 3 homolog, Mesenteric estrogen-dependent adipose 4

All UniProt accessions (2): Q5VYS4, H0Y831

UniProt curated annotations — full annotation on UniProt →

Function. Involved in processes that promote adipocyte differentiation, lipid accumulation, and glucose uptake in mature adipocytes.

Subcellular location. Cytoplasm.

Tissue specificity. Highly expressed in the visceral fat depot.

Isoforms (2)

UniProt ID	Names	Canonical?
Q5VYS4-1	1	yes
Q5VYS4-2	2

RefSeq proteins (1): NP_116238* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR043460	MEDAG/TEX26	Family

UniProt features (4 total): splice variant 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5VYS4-F1	75.32	0.44

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 95 (showing top): HORIUCHI_WTAP_TARGETS_DN, GOBP_REGULATION_OF_FAT_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_FAT_CELL_DIFFERENTIATION, GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP, DAWSON_METHYLATED_IN_LYMPHOMA_TCL1, GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION, GOBP_FAT_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, GRYDER_PAX3FOXO1_TOP_ENHANCERS, HATADA_METHYLATED_IN_LUNG_CANCER_UP, RORA2_01, WONG_ADULT_TISSUE_STEM_MODULE, CHICAS_RB1_TARGETS_SENESCENT, MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_UP

GO Biological Process (1): positive regulation of fat cell differentiation (GO:0045600)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
fat cell differentiation	1
positive regulation of cell differentiation	1
regulation of fat cell differentiation	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

598 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MEDAG	B3GLCT	Q6Y288	590
MEDAG	SCARB2	Q14108	461
MEDAG	CD36	P16671	460
MEDAG	SCARB1	Q8WTV0	455
MEDAG	SAXO5	Q8NA69	451
MEDAG	OPN5	Q6U736	441
MEDAG	TRAPPC5	Q8IUR0	435
MEDAG	ZC2HC1C	Q53FD0	433
MEDAG	ALOX5AP	P20292	408
MEDAG	INSR	P06213	384
MEDAG	PRDM5	Q9NQX1	360
MEDAG	SPP1	P10451	352
MEDAG	CDX4	O14627	348
MEDAG	PEX11G	Q96HA9	340
MEDAG	DGKI	O75912	325

IntAct

14 interactions, top by confidence:

A	B	Type	Score
MEDAG	CATIP	psi-mi:“MI:0915”(physical association)	0.560
MEDAG	ATPAF2	psi-mi:“MI:0915”(physical association)	0.560
MEDAG	TOLLIP	psi-mi:“MI:0915”(physical association)	0.560
SYNJ2BP	MEDAG	psi-mi:“MI:0915”(physical association)	0.560
TRAF6	MEDAG	psi-mi:“MI:0915”(physical association)	0.000
CATIP	MEDAG	psi-mi:“MI:0915”(physical association)	0.000
TOLLIP	MEDAG	psi-mi:“MI:0915”(physical association)	0.000
ATPAF2	MEDAG	psi-mi:“MI:0915”(physical association)	0.000
SYNJ2BP	MEDAG	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (6): MEDAG (Two-hybrid), CATIP (Two-hybrid), ATPAF2 (Two-hybrid), SYNJ2BP (Two-hybrid), MEDAG (Proximity Label-MS), MEDAG (Affinity Capture-MS)

ESM2 similar proteins: A1DL98, A1XIQ0, A2AVJ0, A4UHQ4, F1QGC8, O36381, O74982, O76616, O88738, P02890, P02891, P02892, P06435, P0CZ24, P16420, P32774, P35259, P49408, P68969, Q0GBX8, Q14BA6, Q1KN21, Q1T763, Q1X6Y6, Q1X709, Q1X711, Q20A00, Q2GKJ2, Q3E744, Q3TDK6, Q58DR0, Q5PQ44, Q5REH8, Q5VYS4, Q5XX03, Q5ZK14, Q66T64, Q6WB97, Q6X1D3, Q6X1D7

Diamond homologs: A4IFN2, Q14BA6, Q5VYS4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

59 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	52
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

621 predictions. Top by Δscore:

Variant	Effect	Δscore
13:30918989:GA:G	donor_gain	1.0000
13:30918991:G:GG	donor_gain	1.0000
13:30921009:TCTA:T	acceptor_loss	1.0000
13:30921010:CTAG:C	acceptor_loss	1.0000
13:30921012:A:AG	acceptor_gain	1.0000
13:30921012:AG:A	acceptor_loss	1.0000
13:30921013:G:GG	acceptor_gain	1.0000
13:30921013:GAAA:G	acceptor_gain	1.0000
13:30921122:TTCAG:T	donor_loss	1.0000
13:30921123:TCAG:T	donor_loss	1.0000
13:30921124:CAG:C	donor_loss	1.0000
13:30921125:AG:A	donor_loss	1.0000
13:30921126:GG:G	donor_loss	1.0000
13:30921127:GTAA:G	donor_loss	1.0000
13:30921128:TAAGC:T	donor_loss	1.0000
13:30921559:A:AG	acceptor_gain	1.0000
13:30921559:AGTTT:A	acceptor_gain	1.0000
13:30921560:G:GA	acceptor_gain	1.0000
13:30921560:GTTT:G	acceptor_gain	1.0000
13:30921560:GTTTG:G	acceptor_gain	1.0000
13:30906791:GAG:G	donor_gain	0.9900
13:30906792:AGGT:A	donor_loss	0.9900
13:30906794:G:GC	donor_loss	0.9900
13:30906795:T:A	donor_loss	0.9900
13:30918986:AAAGA:A	donor_gain	0.9900
13:30918987:AAGA:A	donor_gain	0.9900
13:30918988:AGA:A	donor_gain	0.9900
13:30918989:GAG:G	donor_gain	0.9900
13:30921008:TTCTA:T	acceptor_loss	0.9900
13:30921013:GA:G	acceptor_gain	0.9900

AlphaMissense

1989 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
13:30921039:C:A	N138K	0.998
13:30921039:C:G	N138K	0.998
13:30921122:T:C	L166P	0.997
13:30921646:T:C	F196S	0.997
13:30921562:T:C	F168S	0.996
13:30921645:T:C	F196L	0.996
13:30921647:C:A	F196L	0.996
13:30921647:C:G	F196L	0.996
13:30917445:G:C	R107S	0.995
13:30917445:G:T	R107S	0.995
13:30917453:T:A	I110K	0.995
13:30921026:C:A	A134E	0.995
13:30921634:T:C	F192S	0.995
13:30917444:G:T	R107M	0.994
13:30921107:G:A	G161E	0.994
13:30921730:T:C	L224S	0.994
13:30921772:T:C	F238S	0.994
13:30921775:T:C	L239P	0.994
13:30906613:C:A	A33D	0.993
13:30921112:A:C	S163R	0.993
13:30921114:T:A	S163R	0.993
13:30921114:T:G	S163R	0.993
13:30921667:A:T	D203V	0.993
13:30921035:T:A	V137E	0.992
13:30921666:G:C	D203H	0.992
13:30906619:T:C	L35P	0.991
13:30917444:G:C	R107T	0.991
13:30917453:T:G	I110R	0.991
13:30921047:A:G	H141R	0.991
13:30921633:T:C	F192L	0.991

dbSNP variants (sampled 300 via entrez): RS1000087172 (13:30917593 A>C), RS1000132803 (13:30906453 G>A), RS1000246387 (13:30912304 G>C), RS1000442227 (13:30910473 C>T), RS1000475961 (13:30907727 A>G), RS1000714495 (13:30915836 C>T), RS1000745146 (13:30904454 T>C), RS1001020197 (13:30915981 C>A), RS1001398831 (13:30918591 C>G,T), RS1001406229 (13:30913452 A>G), RS1001558687 (13:30924655 T>A,C), RS1001606171 (13:30925039 C>T), RS1001690544 (13:30913637 A>G,T), RS1001707784 (13:30913521 C>A), RS1002145050 (13:30909258 C>T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003124_35	Mild influenza (H1N1) infection	2.000000e-08
GCST003125_9	Influenza A (H1N1) infection	2.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:1001488	influenza A (H1N1)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression, increases expression, increases methylation	3
potassium chromate(VI)	affects cotreatment, decreases expression	2
entinostat	increases expression, affects cotreatment	2
Nickel	increases expression	2
Valproic Acid	affects expression, decreases expression	2
nickel sulfate	decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
chromium hexavalent ion	decreases expression	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	1
2,2’,4,4’,5-brominated diphenyl ether	increases expression	1
dorsomorphin	increases expression, decreases expression, affects cotreatment	1
incobotulinumtoxinA	increases expression	1
Acetaminophen	increases expression	1
Chenodeoxycholic Acid	affects cotreatment, increases expression	1
Deoxycholic Acid	affects cotreatment, increases expression	1
Diazinon	increases methylation	1
Doxorubicin	increases expression	1
Estradiol	affects cotreatment, increases expression	1
Glycochenodeoxycholic Acid	affects cotreatment, increases expression	1
Glycocholic Acid	affects cotreatment, increases expression	1
Glycodeoxycholic Acid	increases expression, affects cotreatment	1
Phthalic Acids	decreases methylation	1
Progesterone	increases expression	1
Silicon Dioxide	increases expression	1
Smoke	decreases expression	1
Tartrazine	affects cotreatment, increases expression	1
Thimerosal	affects cotreatment, decreases expression	1
Tretinoin	increases expression	1
Triclosan	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.